Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biothera Appoints Research SVP | Contract Pharma
Breaking News, Promotions & Moves

Biothera Appoints Research SVP

Graff brings extensive drug discovery and development experience

Jeremy R. Graff, Ph.D., has been appointed senior vice president of Research for Biothera’s Pharmaceutical Group. Most recently, Dr. Graff served as a research fellow and group leader, Oncology Patient Tailoring at Eli Lilly and Co.
 
Dr. Graff has extensive experience across drug discovery and development having led numerous programs from target inception through early and late stage clinical development. He led the efforts to establish the therapeutic mechanism of action for numerous early phase clinical assets, most notably the small molecule kinase inhibitor, enzastaurin, in Diffuse Large B Cell Lymphoma and glioblastoma. Most recently, he shared responsibility for developing and leading translational oncology efforts at Lilly.
 
Dr. Graff has published nearly 60 research articles that have garnered more than 14,000 research citations. He currently serves as a senior reviews editor and associate editor for Cancer Research.
 
“Dr. Graff’s career defines excellence in research and we are delighted to welcome him to Biothera,” said Dan Conners, Biothera Pharmaceutical group president. “We believe he will make significant contributions to the mechanistic understanding of our cancer immunotherapeutic, Imprime PGG, which we hope will ultimately benefit patients in the clinic.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters